

Initial Date: 07/19/2023
Revised Date: 12/10/2025

Section: 9-38R

Ondansetron

Pharmacological Category: Antiemetic

Indications:

1. Nausea and vomiting

Routes: IV/IM; ODT (for patients ≥ 30 kg)

Contraindications:

1. Patients with Phenylketonuria (PKU)

Precautions:

1. Do not administer ODT to patients that are actively vomiting

Expected effects:

1. Diminished nausea

Side effects:

1. Headache
2. Dry mouth
3. Drowsiness

Notes:

1. Orally Disintegrating Tablet (ODT) is an MCA optional medication and may not be available.

Dosing: NAUSEA & VOMITING

Indication: Nausea & vomiting

Adults > 30 kg administer:

1. Ondansetron ODT 4mg one time if not actively vomiting and ODT is available.

Adults administer:

2. Ondansetron 4mg IV/IM if patient is actively vomiting, vomited post ODT administration, or ODT is not available.

Initial Date: 07/19/2023

Revised Date: 12/10/2025

Section: 9-38R

3. May administer a second dose of ondansetron 4 mg IV/IM only, 15 minutes after first dose IV/IM if nausea/vomiting persists. Total dose (including ODT) not to exceed 8 mg.

Pediatrics $\geq$ 30 kg administer:

1. Ondansetron ODT 4mg one time if not actively vomiting and ODT is available.

Pediatrics administer:

2. Ondansetron 0.1 mg/kg IV/IM (max dose 4 mg) if patient is actively vomiting, vomited post ODT administration, or ODT is not available.
3. May administer a second dose of ondansetron 0.1 mg/kg (max dose 4 mg) IV/IM only, 15 minutes after first dose IV/IM if nausea/vomiting persists. Total dose (including ODT) not to exceed 8 mg.

Used in the Following Protocol(s):

Nausea & Vomiting (Section 1 General Treatment)